The Impact of P-Glycoprotein on the Disposition of Drugs Targeted for Indications of the Central Nervous System: Evaluation Using the Mdr1a/1b Knockout Mouse Model

Abstract

ABSTRACT:Thirty-two structurally diverse drugs used for the treatment of various conditions of the central nervous system (CNS), along with two active metabolites, and eight non-CNS drugs were measured in brain, plasma, and cerebrospinal fluid in the P-glycoprotein (P-gp) knockout mouse model after subcutaneous administration, and the data were compared with corresponding data obtained in wild-type mice. Total brain-to-plasma (B/P) ratios for the CNS agents ranged from 0.060 to 24. Of the 34 CNS-active agents, only 7 demonstrated B/P area under the plasma concentration curve ratios between P-gp knockout and wild-type mice that did not differ significantly from unity. Most of the remaining drugs demonstrated 1.1-to 2.6-fold greater B/P ratios in P-gp knockout mice versus wild-type mice. Three, risperidone, its active metabolite 9-hydroxyrisperidone, and metoclopramide, showed marked differences in B/P ratios between knockout and wild-type mice (6.6-to 17-fold). Differences in B/P ratios and cerebrospinal fluid/ plasma ratios between wild-type and knockout animals were correlated. Through the use of this model, it appears that most CNSactive agents demonstrate at least some P-gp-mediated transport that can affect brain concentrations. However, the impact for the majority of agents is probably minor. The example of risperidone illustrates that even good P-gp substrates can still be clinically useful CNS-active agents. However, for such agents, unbound plasma concentrations may need to be greater than values projected using receptor affinity data to achieve adequate receptor occupancy for effect.Active transport mechanisms as determinants of drug absorption, distribution, and clearance have been the focus of considerable research effort over the past decade. Of the numerous transporter proteins recently investigated, the one for which the greatest amount of knowledge exists is P-glycoprotein (MDR1). Originally described as a transporter involved in imparting drug resistance to tumor cells, P-glycoprotein has been demonstrated to be important in reducing absorption of drugs from the intestinal lumen, in active secretion of drugs into urine and bile, and in extrusion of drugs from vital organs such as the brain and reproductive tissues (Troutman et al., 2002). As such, P-glycoprotein-mediated transport has become an important issue in the discovery and development of new drugs. For example, new compounds that are promising with regard to target receptor/ enzyme activity can be severely hampered in their ability to elicit pharmacological effects in vivo should they be good substrates for P-glycoprotein, especially if the route of administration is intended to be oral or the target tissues is one rich in P-glycoprotein activity. Furthermore, the potential for drug-drug interactions arises in the event that the P-glycoprotein substrate is coadministered with another agent that can inhibit P-glycoprotein.Several models have been developed to assess drugs as P-glycoprotein substrates. In vitro models have included the Caco...

Effects on enantiomeric drug disposition and open-field behavior after chronic treatment with venlafaxine in the P-glycoprotein knockout mice model

“…For example, studies in Caco-2 cells have given contradicting results for venlafaxine (Ehret et al 2007;Oganesian et al 2009). The antidepressant drug citalopram is another example where different results have been reported in vitro (Rochat et al 1999) and in vivo Doran et al 2005). To study Odm-venlafaxine (desvenlafaxine) and Ndm-venlafaxine separately in our mice model would be of high interest to further elucidate this important issue.…”

“…Several pharmacokinetic studies have been published using the abcb1ab knockout mouse model and P-gp has been shown to significantly limit brain entry of a wide variety of drugs including venlafaxine (Doran et al 2005;Kirschbaum et al 2010;Uhr et al 2000;Uhr et al 2008). Using this animal model, we have recently shown that P-gp decreases the brain penetration of the S-and R-enantiomers of venlafaxine and its metabolites after an acute drug challenge (Karlsson et al 2010).…”

The role of brain barriers in fluid movement in the CNS: is there a ‘glymphatic’ system?

“…Doran et al [52] very helpfully studied a library of Pfizer's small molecule drugs < 450 Da, measuring both brain and CSF uptake in mice after systemic administration. Reanalysis of their data (Fig.…”

Drug metabolism and pharmacokinetics, the blood-brain barrier, and central nervous system drug discovery

“…However, for such agents, unbound plasma concentrations may need to be greater than values projected using receptor affinity data to achieve adequate receptor occupancy for effect. 57 There have been attempts to establish quantitative structure-activity relationship (QSAR) for P-gp, 58 but the task is made difficult by the broad specificity of this transporter.…”